Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248432874> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4248432874 endingPage "4501" @default.
- W4248432874 startingPage "4501" @default.
- W4248432874 abstract "4501 Background: Durable progression-free survival (PFS) rates for pts with intermediate- and poor-risk GCT approximate only 75% and 50%, respectively with standard BEP. This multicenter phase II study investigated first-line TIP in this population. Methods: Pts age ≥18 with untreated, IGCCCG intermediate- (LDH modified to ≥3x upper limit of normal) or poor-risk GCT were eligible. Pts received 4 cycles of TIP every 21 days, consisting of paclitaxel 120mg/m 2 days 1-2; ifosfamide 1200mg/m 2 days 1-5; and cisplatin 20mg/m 2 days 1-5, followed by G-CSF and levofloxacin for neutropenic fever prophylaxis. The primary endpoint was the complete response (CR) rate; secondary endpoints included PFS and toxicity. A Simon’s 2-stage design required a CR in ≥11/18 pts to proceed to stage 2, where with ≥27/41 CRs overall, the regimen would be considered active and worthy of further study. Results: Of 44 men (median age 27) enrolled; 38 had nonseminoma and 6 seminoma; 29 were poor-risk and 15 intermediate-risk. Primary site was testis in 30, mediastinum in 11, and retroperitoneum in 3. 42 pts had elevated markers and 14, 6, and 1 had liver, bone, and brain metastasis, respectively. The trial met its primary endpoint; of 41 evaluable pts, 28 achieved a CR (see Table) and 6 pts (5 with seminoma) achieved a partial response with negative markers (PR-). Two pts relapsed. With a median follow-up of 2.2 years, estimated 3-year PFS was 79% and 3-year overall survival (OS) 98% (see Table). There were no treatment-related deaths. Grade 3/4 toxicities were primarily hematologic and 6 (14%) pts developed neutropenic fever. Conclusions: TIP demonstrates promising efficacy and is well-tolerated in intermediate- and poor-risk GCT pts. A randomized trial of TIP vs. BEP has been initiated to compare efficacy. Clinical trial information: NCT00470366. [Table: see text]" @default.
- W4248432874 created "2022-05-12" @default.
- W4248432874 creator A5006005566 @default.
- W4248432874 creator A5008235255 @default.
- W4248432874 creator A5016285137 @default.
- W4248432874 creator A5018531384 @default.
- W4248432874 creator A5029708659 @default.
- W4248432874 creator A5031088617 @default.
- W4248432874 creator A5037495211 @default.
- W4248432874 creator A5037506402 @default.
- W4248432874 creator A5045476835 @default.
- W4248432874 creator A5049998855 @default.
- W4248432874 creator A5059063118 @default.
- W4248432874 creator A5062419531 @default.
- W4248432874 creator A5064884168 @default.
- W4248432874 creator A5069016387 @default.
- W4248432874 creator A5069656105 @default.
- W4248432874 creator A5091696839 @default.
- W4248432874 date "2013-05-20" @default.
- W4248432874 modified "2023-10-17" @default.
- W4248432874 title "Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)." @default.
- W4248432874 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.4501" @default.
- W4248432874 hasPublicationYear "2013" @default.
- W4248432874 type Work @default.
- W4248432874 citedByCount "1" @default.
- W4248432874 countsByYear W42484328742015 @default.
- W4248432874 crossrefType "journal-article" @default.
- W4248432874 hasAuthorship W4248432874A5006005566 @default.
- W4248432874 hasAuthorship W4248432874A5008235255 @default.
- W4248432874 hasAuthorship W4248432874A5016285137 @default.
- W4248432874 hasAuthorship W4248432874A5018531384 @default.
- W4248432874 hasAuthorship W4248432874A5029708659 @default.
- W4248432874 hasAuthorship W4248432874A5031088617 @default.
- W4248432874 hasAuthorship W4248432874A5037495211 @default.
- W4248432874 hasAuthorship W4248432874A5037506402 @default.
- W4248432874 hasAuthorship W4248432874A5045476835 @default.
- W4248432874 hasAuthorship W4248432874A5049998855 @default.
- W4248432874 hasAuthorship W4248432874A5059063118 @default.
- W4248432874 hasAuthorship W4248432874A5062419531 @default.
- W4248432874 hasAuthorship W4248432874A5064884168 @default.
- W4248432874 hasAuthorship W4248432874A5069016387 @default.
- W4248432874 hasAuthorship W4248432874A5069656105 @default.
- W4248432874 hasAuthorship W4248432874A5091696839 @default.
- W4248432874 hasConcept C126322002 @default.
- W4248432874 hasConcept C126894567 @default.
- W4248432874 hasConcept C141071460 @default.
- W4248432874 hasConcept C143998085 @default.
- W4248432874 hasConcept C203092338 @default.
- W4248432874 hasConcept C2776694085 @default.
- W4248432874 hasConcept C2776938808 @default.
- W4248432874 hasConcept C2777506904 @default.
- W4248432874 hasConcept C2778239845 @default.
- W4248432874 hasConcept C2781413609 @default.
- W4248432874 hasConcept C2908647359 @default.
- W4248432874 hasConcept C31760486 @default.
- W4248432874 hasConcept C535046627 @default.
- W4248432874 hasConcept C71924100 @default.
- W4248432874 hasConcept C90924648 @default.
- W4248432874 hasConcept C99454951 @default.
- W4248432874 hasConceptScore W4248432874C126322002 @default.
- W4248432874 hasConceptScore W4248432874C126894567 @default.
- W4248432874 hasConceptScore W4248432874C141071460 @default.
- W4248432874 hasConceptScore W4248432874C143998085 @default.
- W4248432874 hasConceptScore W4248432874C203092338 @default.
- W4248432874 hasConceptScore W4248432874C2776694085 @default.
- W4248432874 hasConceptScore W4248432874C2776938808 @default.
- W4248432874 hasConceptScore W4248432874C2777506904 @default.
- W4248432874 hasConceptScore W4248432874C2778239845 @default.
- W4248432874 hasConceptScore W4248432874C2781413609 @default.
- W4248432874 hasConceptScore W4248432874C2908647359 @default.
- W4248432874 hasConceptScore W4248432874C31760486 @default.
- W4248432874 hasConceptScore W4248432874C535046627 @default.
- W4248432874 hasConceptScore W4248432874C71924100 @default.
- W4248432874 hasConceptScore W4248432874C90924648 @default.
- W4248432874 hasConceptScore W4248432874C99454951 @default.
- W4248432874 hasIssue "15_suppl" @default.
- W4248432874 hasLocation W42484328741 @default.
- W4248432874 hasOpenAccess W4248432874 @default.
- W4248432874 hasPrimaryLocation W42484328741 @default.
- W4248432874 hasRelatedWork W2061915529 @default.
- W4248432874 hasRelatedWork W2088035700 @default.
- W4248432874 hasRelatedWork W2091145914 @default.
- W4248432874 hasRelatedWork W2121713339 @default.
- W4248432874 hasRelatedWork W2466567915 @default.
- W4248432874 hasRelatedWork W2473626106 @default.
- W4248432874 hasRelatedWork W2523147384 @default.
- W4248432874 hasRelatedWork W4235918068 @default.
- W4248432874 hasRelatedWork W4251576511 @default.
- W4248432874 hasRelatedWork W4253511704 @default.
- W4248432874 hasVolume "31" @default.
- W4248432874 isParatext "false" @default.
- W4248432874 isRetracted "false" @default.
- W4248432874 workType "article" @default.